Consequences of the 118A>G polymorphism in the OPRMI gene: Translation from bench to bedside?

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 331-353

  Mura, Elisa ^a   Govoni, Stefano ^a   Racchi, Marco ^a   Carossa, Valeria ^a   Nadia Ranzani, Guglielmina ^a   Allegri, Massimo ^a,b   van Schaik, Ron H N ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

opioid receptor; Analgesia; Opioids; Pain; Pharmacogenetics

Indexed keywords

BETA ENDORPHIN; CATECHOL METHYLTRANSFERASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; MESSENGER RNA; METHADONE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MORPHINE 3 GLUCURONIDE; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE; OXYCODONE; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; ANALGESIC ACTIVITY; ANOREXIA; BINDING AFFINITY; BIOASSAY; BIOLOGICAL MODEL; CATECHOL O METHYLTRANSFERASE GENE; CENTRAL NERVOUS SYSTEM DEPRESSION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; ENZYME PHOSPHORYLATION; FATIGUE; GAIN OF FUNCTION MUTATION; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HALLUCINATION; HAPLOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE PRURITUS; LOSS OF FUNCTION MUTATION; MOLECULAR DYNAMICS; MU OPIOID RECEPTOR 1 GENE; MYOCLONUS; NAUSEA; NIGHTMARE; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN THRESHOLD; PHARMACOGENOMICS; POSTOPERATIVE PAIN; PROTEIN EXPRESSION; PRURITUS; RECEPTOR DOWN REGULATION; RECEPTOR GENE; RESPIRATION DEPRESSION; REVIEW; REWARD; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; TRANSGENIC MOUSE; VOMITING; WILD TYPE;

EID: 84877892328     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S42040     Document Type: Review

References (98)

1. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(Suppl 2):S105-S120.
2. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490-518.
3. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9): 2133-2150.
4. Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther. 1994;268(1):1-9.
5. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991;13(1):1-23.
6. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996;64(2):357-364.
7. Cepeda MS, Farrar JT, Roa JH, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2001;70(4):351-361.
8. Ozalp G, Sarioglu R, Tuncel G, Aslan K, Kadiogullari N. Preoperative emotional states in patients with breast cancer and postoperative pain. Acta Anaesthesiol Scand. 2003;47(1):26-29.
9. Aubrun F, Salvi N, Coriat P, Riou B. Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology. 2005;103(1):156-160.
10. Allegri M, De Gregori M, Niebel T, et al. Pharmacogenetics and postoperative pain: a new approach to improve acute pain management. Minerva Anestesiol. 2010;76(11):937-944.
11. Shabalina SA, Zaykin DV, Gris P, et al. Expansion of the human muopioid receptor gene architecture: novel functional variants. Hum Mol Genet. 2009;18(6):1037-1051.
12. Pasternak GW. Molecular insights into mu opioid pharmacology: From the clinic to the bench. Clin J Pain. 2010;26 Suppl 10: S3-S9.
13. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012;441(1): 379-386.
14. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A > G genetic variant for pain treatment. Pain. 2009;146(3): 270-275.
15. Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth. 1998;81(1):12-19.
16. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95(16):9608-9613.
17. Trigo JM, Martin-García E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 2010;108(3):183-194.
18. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276(5):3130-3137.
19. Beyer A, Koch T, Schröder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89(3):553-560.
20. Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V. Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G singlenucleotide polymorphism. J Neurophysiol. 2007;97(2):1058-1067.
21. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem. 2007;103(1): 77-87.
22. Oertel BG, Kettner M, Scholich K, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530-6535.
23. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol. 2005;5(1):60-68.
24. Fan P, Jiang Z, Diamond I, Yao L. Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons. Mol Pharmacol. 2009;76(3):526-533.
25. Narita M, Ioka M, Suzuki M, Narita M, Suzuki T. Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain. Neurosci Lett. 2002;324(2): 97-100.
26. Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem. 1992;58(3):1168-1171.
27. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51(1-2):23-47.
28. Nestler EJ. Molecular neurobiology of addiction. Am J Addict. 2001;10(3):201-217.
29. Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem. 2002;78(3):637-647.
30. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem. 2010;112(2):486-496.
31. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280(38):32618-32624.
32. Ray R, Ruparel K, Newberg A, et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A. 2011;108(22):9268-9273.
33. Lerman C, Wileyto EP, Patterson F, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004;4(3):184-192.
34. Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet. 2003;120B(1):97-108.
35. Hoehe MR, Köpke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;9(19):2895-2908.
36. Pang GS, Wang J, Wang Z, Goh C, Lee CG. The G allele of SNP E1/A118G at the mu-opioid receptor gene locus shows genomic evidence of recent positive selection. Pharmacogenomics. 2009;10(7): 1101-1109.
37. Oertel BG, Doehring A, Roskam B, et al. Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet. 2012;21(21):4751-4760.
38. Johnson AD, Zhang Y, Papp AC, et al. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics. 2008;18(9):781-791.
39. Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK. A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol Psychiatry. 2004;9(1):99-108.
40. Barr CS, Chen SA, Schwandt ML, et al. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry. 2010;67(1):78-80.
41. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A. 2009; 106(26):10847-10852.
42. Wang YJ, Huang P, Ung A, Blendy JA, Liu-Chen LY. Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience. 2012;205:178-184.
43. Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2011;16(8):809-817.
44. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009;89(2):649-705.
45. Weiss F, Lorang MT, Bloom FE, Koob GF. Oral alcohol selfadministration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther. 1993;267(1):250-258.
46. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-5278.
47. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 2003;49(4):226-231.
48. Mahmoud S, Thorsell A, Sommer WH, et al. Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca2+ channels in humanized mouse sensory neurons. Anesthesiology. 2011;115(5):1054-1062.
49. Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6(3):159-167.
50. Zhang W, Chang YZ, Kan QC, et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia. 2010;65(2): 130-135.
51. Lötsch J, Stuck B, Hummel T. The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation. Behav Neurosci. 2006;120(6):1218-1224.
52. Huang CJ, Liu HF, Su NY, et al. Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females*. Anaesthesia. 2008;63(12):1288-1295.
53. Fukuda K, Hayashida M, Ide S, et al. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain. 2009;147(1-3):194-201.
54. Fukuda K, Hayashida M, Ikeda K, Koukita Y, Ichinohe T, Kaneko Y. Diversity of opioid requirements for postoperative pain control following oral surgery - is it affected by polymorphism of the μ-opioid receptor? Anesth Prog. 2010;57(4):145-149.
55. Chou WY, Yang LC, Lu HF, et al. Association of mu-opioid receptorgene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006;50(7):787-792.
56. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Humanopioid receptor A118G polymorphism affects intravenous patientcontrolled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006;105(2):334-337.
57. Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patientcontrolled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology. 2008;109(3):520-526.
58. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain. 2009;5:32.
59. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006;79(4):316-324.
60. Wong CA, McCarthy RJ, Blouin J, Landau R. Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia. Int J Obstet Anesth. 2010;19(3):246-253.
61. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study ofthe OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol. 2011;77(1):33-39.
62. Wu WD, Wang Y, Fang YM, Zhou HY. Polymorphism of the micro-opioid receptor gene (OPRM1 118A > G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther. 2009;13(5):331-337.
63. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain. 2008;139(1):5-14.
64. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol. 2010;24(4):517-524.
65. Zwisler ST, Enggaard TP, Mikkelsen S, et al. Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol. 2012;52:234-242.
66. Klepstad P, Rakvåg TT, Kaasa S, et al. The 118A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232-1239.
67. Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12(1):3-9.
68. Lötsch J, Kobal G, Geisslinger G. No contribution of morphine-6-- glucuronide to clinical morphine effects after short-term administration. Clin Neuropharmacol. 1998;21(6):351-354.
69. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324-336.
70. Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg. 2006;103(4):1011-1017.
71. Lötsch J, von Hentig N, Freynhagen R, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009;19(6):429-436.
72. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008;9(11):1605-1616.
73. Argoff C. Mechanisms of pain transmission and pharmacologic management. Curr Med Res Opin. 2011;27(10):2019-2031.
74. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243-250.
75. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158 met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240-1243.
76. Reyes-Gibby CC, Shete S, Rakvåg T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130(1-2):25-30.
77. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758.
78. Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg. 2011;112(2):448-453.
79. Romberg RR, Olofsen E, Bijl H, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A > G) does not protect against opioidinduced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102(3):522-530.
80. Zhang L, Kendler KS, Chen X. The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct. 2006;2:28.
81. Ray R, Jepson C, Patterson F, et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl). 2006;188(3):355-363.
82. Perkins KA, Lerman C, Grottenthaler A, et al. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol. 2008;19(5-6): 641-649.
83. Wang Z, Ray R, Faith M, et al. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci Lett. 2008;438(3): 275-280.
84. van der Zwaluw CS, van den Wildenberg E, Wiers RW, et al. Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. Pharmacogenomics. 2007;8(10):1427-1436.
85. Bart G, Heilig M, LaForge KS, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry. 2004;9(6): 547-549.
86. Drakenberg K, Nikoshkov A, Horváth MC, et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A. 2006;103(20):7883-7888.
87. Szeto CY, Tang NL, Lee DT, Stadlin A. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport. 2001;12(6):1103-1106.
88. Tan EC, Tan CH, Karupathivan U, Yap EP. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport. 2003;14(4):569-572.
89. Glatt SJ, Bousman C, Wang RS, et al. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and metaanalysis. Drug Alcohol Depend. 2007;90(2-3):159-165.
90. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002;19(4):459-460.
91. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3): 262-268.
92. Sora I, Elmer G, Funada M, et al. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology. 2001;25(1):41-54.
93. Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011;63(4):1001-1019.
94. Bianchi M, Fornasari D, Antonini RA, Beretta-Piccoli BT, Nava S,Neuenschwander H. The pharmacogenetics of morphine-induced analgesia: a case report. J Pain Symptom Manage. 2008;36(1): e10-e12.
95. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570-587.
96. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.
97. Ballina LE, Ulirsch JC, Soward AC, et al. μ-Opioid receptor gene A118G polymorphism predicts pain recovery after sexual assault. J Pain. 2013;14(2):165-171.
98. Caraceni A, Hanks G, Kaasa S, et al; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-e68.